Community/Retail

Ongoing measles outbreaks highlight the impacts of reduced vaccination rates and heightened public distrust in health experts.

Biosimilars lower biologic costs and widen access.

Phase 2 trial finds combination therapy resulted in 22% body weight reduction at 72 weeks, with 92% of weight loss attributable to fat mass, addressing concerns about muscle loss with GLP-1 receptor agonists.

Ronna Hauser breaks down findings showing that delayed manufacturer refunds under the Medicare Drug Price Negotiation Program are forcing retail pharmacies to minimize high-dollar drug inventory and dip into savings to stay afloat.

Andrew Shao, PhD, senior vice president for global regulatory and scientific affairs at Niagen Bioscience, discusses how increased consumer access to information has shifted the supplement landscape toward greater demand for clinically validated products and transparency. He highlights the critical role pharmacists play in guiding consumers toward evidence-based supplements, while emphasizing the need for stronger regulatory enforcement and industry accountability to improve trust and product quality.

A preclinical mucosal C difficile vaccine clears spores and prevents recurrence in animals, hinting at new protection for high‑risk patients.

The experts express their concerns that current ACIP decisions and guidelines are not backed by "pure science."

Patients receiving dialysis with primary care physicians had lower rates of emergency department visits compared with those without primary care involvement.

A 4-day course of a mycelium-based supplement reduced reactogenicity and sustained antibody levels for up to 6 months in COVID-naive participants.

OTC naloxone nasal sprays expand overdose rescue; pharmacists guide proper use, tackle stigma, and help communities curb opioid deaths.

A large observational study identifies U-shaped relationship between weekday sleep duration and estimated glucose disposal rate.

Niagen Bioscience’s NAD research, patents, and clinical trials, plus pharmacist-led supplement education to help consumers choose evidence-based vitamins and supplements.

Experts discuss guideline adoption, therapeutic advances, and team-based care.

Adherence to glucose-lowering drugs ranges from 41% to 68% depending on drug class.

Early detection and prevention reduce risks of diverse adverse drug reactions.

Look‑alike, soundalike drugs increase errors, but systems can prevent them.

To combat vaccine-related misinformation and disinformation, the speakers emphasize the importance of integrated education, community-led advocacy, and proactive outreach.

The FDA approves Bristol Myers Squibb’s deucravacitinib (Sotyktu), a first oral tyrosine kinase 2 inhibitor for active psoriatic arthritis.

Pharmacists quietly prevent medication harm, ease discharge chaos, and manage rising health care strain through unseen cognitive work.

Explore how limited FDA enforcement impacts vitamins and supplements, as pharmacists push industry transparency with independent testing, COAs, and research-backed quality.

Peptide compounders face rising scrutiny as regulators and lawsuits zero in on adherence to established compounding standards.

NCPA President Kristen Riddle recaps the organization's Multiple Locations Conference.

As the spring travel season approaches, more than 30 countries appear on the CDC's circulating polio alert list.

New AAAAI data spotlight oral remibrutinib for CSU, next-generation peanut allergy therapies, infant microbiome prevention, and GLP‑1 receptor agonists linked to fewer asthma flares.

The second part of this video series highlights thoughts from 4 panelists on shared clinical decision-making and how harmful misinformation is in the health care space.

Meta-analysis finds insulin efsitora provides similar glycemic control with superior hemoglobin A1C reduction at 52 weeks and lower total weekly insulin dose, while maintaining an acceptable safety profile.

A single intranasal formulation demonstrated protection against SARS-CoV-2, bacterial pneumonia, and allergens for up to 3 months in preclinical models.

Consumers seek clinically validated supplements as health information spreads quickly; Niagen Bioscience stresses independent evidence, and pharmacists guide choices using trusted certifications.